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http://dx.doi.org/10.1016/j.pedneo.2Nebulized hypertonic saline (HS) treatment reduced the length of hospitalization in infants
with acute bronchiolitis in a previous meta-analysis. However, there was no reduction in the
admission rate. We hypothesized that nebulized HS treatment might significantly decrease
both the duration and the rate of hospitalization if more randomized controlled trials (RCTs)
were included. We searched MEDLINE, PubMed, CINAHL, and the Cochrane Central Register
of Controlled Trials (CENTRAL) without a language restriction. A meta-analysis was per-
formed based on the efficacy of nebulized HS treatment in infants with acute bronchiolitis.
We used weighted mean difference (WMD) and risk ratio as effect size metrics. Eleven
studies were identified that enrolled 1070 infants. Nebulized HS treatment significantly
decreased the duration and rate of hospitalization compared with nebulized normal saline
(NS) [duration of hospitalization: WMD Z 0.96, 95% confidence interval (CI) Z 1.38 to
0.54, p < 0.001; rate of hospitalization: risk ratio Z 0.59, 95% CI Z 0.37e0.93,
pZ 0.02]. Furthermore, nebulized HS treatment had a beneficial effect in reducing the clin-
ical severity (CS) score of acute bronchiolitis infants post-treatment (Day 1: WMD Z 0.77,
95% CI Z 1.30 to 0.24, p Z 0.005; Day 2: WMD Z 0.85, 95% CI Z 1.30 to 0.39,
p < 0.001; Day 3: WMD Z 1.14, 95% CI Z 1.69 to 0.58, p < 0.001). There was no
decrease in the rate of readmission (risk ratio Z 1.08, 95% CI Z 0.68e1.73, p Z 0.74).of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, 539, Zhongxiao Road, Chiayi
(H.H. Chou).
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432 Y.-J. Chen et alNebulized HS treatment significantly decreased both the rate and the duration of hospital-
ization. Due to the efficacy and cost-effectiveness, HS should be considered for the treat-
ment of acute bronchiolitis in infants.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Acute bronchiolitis is a viral infection that occurs in chil-
dren most commonly in the first 2 years of life and is
characterized by respiratory symptoms, resulting in
wheezing and/or crackles upon auscultation. It is usually a
self-limiting illness. However, this condition may be asso-
ciated with several severe complications, such as apnea,
respiratory failure, or secondary bacterial infection.1,2 The
mainstay of treatment in bronchiolitis includes supportive
care such as oxygenation and maintenance of hydration.3
Theoretically, by absorbing water from the mucosa and
sub-mucosa through hyperosmolarity, hypertonic saline
(HS) solution has the potential to reduce airway edema and
improve the clearance of mucus plugging and thus increase
mucociliary transit time inside the bronchiolar lumen.4,5 A
Cochrane review with a meta-analysis of seven trials
revealed that nebulized 3% HS significantly reduced the
length of hospital stay and improved the clinical severity
(CS) score among infants.6 Nevertheless, there was no sig-
nificant reduction in the rate of hospitalization. The sample
size assessed for admission rate in the Cochrane review was
relatively small, including only three trials. We hypothe-
sized that nebulized HS treatment might significantly
decrease both the duration and the rate of hospitalization
if more randomized controlled trials (RCTs) were included
in the published Cochrane review. Therefore, we per-
formed an updated meta-analysis of currently available
RCTs and quasi-RCTs to assess the effectiveness and safety
of the nebulized HS treatment for acute bronchiolitis in
infants.
2. Methods
2.1. Inclusion criteria
RCTs or quasi-RCTs (i.e., those trials with inadequate allo-
cation concealment) that recruited infants younger than 24
months with a diagnosis of acute bronchiolitis were
included in this meta-analysis. Acute bronchiolitis was
defined as the first episode of wheezing and/or crackles
upon auscultation, with clinical symptoms of a viral respi-
ratory infection. Both inpatients and outpatients were
included.
2.2. Search strategy
MEDLINE (from 1966 to January 2013), PubMed (from 1966
to January 2013), and CINAHL (from 1982 to January 2013)
databases were searched to identify RCTs. The Cochrane
Central Register of Controlled Trials (CENTRAL) was also
searched. The following medical subject heading terms andtext words were used: (bronchiolitis OR acute wheezing OR
respiratory syncytial virus OR RSV) AND (HS OR 3% saline OR
5% saline) AND (nebulized OR inhaled OR aerosol). We
restricted the search to human studies and no language
restrictions were applied. Additional information was
retrieved via a manual search of references from recent
reviews and relevant published original studies.
2.3. Data extraction
Two reviewers (Y.-J. Chen and W.-L. Lee) independently
reviewed each reference which was identified through the
search, scanned the full texts of relevant studies, applied
the inclusion criteria, and extracted data separately on a
data abstraction form. The reviewers extracted data on the
baseline characteristics of the included trials, the studied
drugs and their doses, the use of placebo or no treatment,
follow-up and loss of follow-up. The primary outcomes of
interest were the rate of hospitalization, the duration of
hospital stay, the rate of readmission, and the CS score.7
This scoring system assesses respiratory rate, wheezing,
retraction, and general condition by assigning a number
from 0 to 3 to each variable, with increased severity
receiving a higher score. One review author (H.-H. Chou)
entered data into Review Manager (RevMan) version 5.0
statistical software (Cochrane Collaboration, Oxford, UK;
RevMan 2009) and the other two authors (Y.-J. Chen and
W.-L. Lee) cross-checked the printout against their own
data abstraction forms.
2.4. Subgroup analysis
We performed exploratory subgroup analyses according to
the source of recruitment of participants (outpatient or
inpatient). The treatment regimen, including the concen-
tration, volume, and frequency of administered saline,
concomitantly inhaled medication and the duration of
treatment, which may contribute to heterogeneity in the
meta-analysis, were analyzed.
2.5. Quality assessment of included studies
The quality of reporting of all included RCTs was deter-
mined according to the Cochrane Collaboration Risk of Bias
instrument.8 We assessed the risk of bias using a domain-
based evaluation, classifying studies primarily according
to their risk of non-random allocation of patients in the
intervention arm (sequence generation) and the conceal-
ment of this process (allocation concealment). Addition-
ally, blinding, incomplete outcome data, and intention-
to-treat analysis were assessed. Disagreements were
resolved via discussions among the authors.
Table 1 Characteristics of the included studies.
Study/year No. of
patients
Setting Inclusion criteria Intervention Primary outcome
Sarrell et al
200210
65 Outpatient Age  24 mo; mild-to-moderate viral
bronchiolitis
Terbutaline 5 mg þ 3% HS 2 mL Q8h
for 5 days
CSS, RA score, AR
Mandelberg
et al 200311
52 Inpatient Age  12 mo; viral bronchiolitis that
leads to hospitalization
Epinephrine 1.5 mg þ 3% HS 4 mL Q8h
until discharge
LOS, change in CSS, RA score, number
of add-on treatments
Tal et al 200612 41 Inpatient Age  12 mo; viral bronchiolitis that
leads to hospitalization
Epinephrine 1.5 mg þ 3% HS 4 mL Q8h
until discharge
CSS, LOS
Kuzik et al
200713
96 Inpatient Age  18 mo; moderately severe viral
bronchiolitis þ RDAI score  4
3% HS 4 mL Q2h for 3 doses, Q4h for 5
doses, Q6h until discharge
LOS, treatment received during study
Grewal et al
200914
46 ED Age 6 wke12 mo; mild-to-moderate
bronchiolitis with SpO2 85
e96% þ RDAI score  4
2.25% epinephrine 0.5 mL þ 3% HS
2.5 mL at 0 and 120 min (if needed)
Change in RDAI score, SpO2, AR,
readmission rate
Anil et al 201016 186 ED Age 6 wke24 mo; mild bronchiolitis
with CSS 1e9
- epinephrine 1.5 mg þ HS 4 mL at
0, 30 min
- salbutamol 2.5 mg þ HS 4 mL at 0,
30 min
CSS, SpO2, HR, AR, readmission rate
Al-Ansari et al
201015
171 Short stay unit
of ED
Age  18 mo; moderately severe viral
bronchiolitis with CSS  4
- epinephrine 1.5 mL þ 3% HS 3.5 mL
Q4h until discharge
- epinephrine 1.5 mL þ 5% HS 3.5 mL
Q4h until discharge
CSS, SaO2, HR
Kuzik et al
201017
88 4 hospitals
(3 in ED, 1 in
outpatient
center)
Age  24 mo; moderately severe viral
bronchiolitis with SaO2  94% þ RDAI
score  4
Salbutamol 1 mg þ HS 4 mL every
20 min for 3 doses
Change in RDAI score, AR, AR within 7
days, unscheduled physician visits
within 7 days
Luo et al 201018 93 Inpatient Age  24 mo; hospitalized with mild
to moderate bronchiolitis (CSS < 9)
Salbutamol 2.5 mg þ HS 4 mL Q8h
until discharge
Duration of wheezing and cough, LOS,
CSS
Ipek et al
201119
120 ED Age 1 moe2 y, viral bronchiolitis with
CSS 4e8
- Salbutamol 0.15 mg/kg þ HS 4 mL
every 20 min for 3 doses
- HS 4 mL every 20 min for 3 doses
Change in CSS, corticosteroid need,
AR, CSS
Luo et al 201120 112 Inpatient Age  24 mo; hospitalized with
moderate to severe bronchiolitis
(CSS > 5)
3% HS 4 mL Q2h for 3 doses, Q4h for 5
doses, Q6h until discharge
Time for relief of wheezing, cough,
LOS, CSS
The data are presented as mean  standard deviation, unless stated otherwise.
AR Z admission rate; CSS Z clinical severity score; ED Z emergency department; HR Z heart rate; HS Z hypertonic saline; LOS Z length of hospital stay; NS Z normal saline; Q2/4/
8h Z every 2/4/8 hours; RA Z radiograph assessment; RDAI Z respiratory distress assessment instrument; SpO2 Z oxygen saturation.
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Table 2 Summary of risk bias assessment.
Study/year Adequate sequence
generation
Allocation
concealment
Blinding of outcome
measurement
Baseline
comparability
Intention-to-treat
analysis
Sarrell et al 200210 Yes Yes Yes Yes Yes
Mandelberg et al 200311 Yes Yes Yes Yes No
Tal et al 200612 Yes Yes Yes Yes No
Kuzik et al 200713 Yes Yes Yes Yes No
Grewal et al 200914 Yes Yes Yes Yes Yes
Anil et al 201016 Yes Yes Yes Yes No
Al-Ansari et al 201015 Yes Yes Yes Yes Yes
Kuzik et al 201017 Yes Yes Yes Yes Yes
Luo et al 201018 Yes Yes Yes Yes No
Ipek et al 201119 Yes No Yes Yes Yes
Luo et al 201120 Yes Yes Yes Yes No
434 Y.-J. Chen et al2.6. Statistical analyses
The primary outcomes of interest were the duration and
the rate of hospitalization. Continuous outcomes were
pooled as a weighted mean difference (WMD), which we
expressed as a standardized mean difference due to the
variations in measurements. The differences in means and
their 95% confidence intervals (CIs) at the end of treatment
were calculated for each trial, and the WMD was used as a
summary estimator. Dichotomous outcome data from indi-
vidual trials were analyzed using the relative risk measure.
A random-effects model was used, followed by a test for
homogeneity. The p values were two-sided, with signifi-
cance set at p < 0.05. We assessed the p value of the c2 test
to determine heterogeneity and I2 to measure inconsis-
tency. We regarded heterogeneity as “not important” when
the I2 value was < 40% and as “considerable” when the I2
value was > 75%.8 All statistical analyses for the meta-
analysis were performed using RevMan 5.0 (Cochrane
Collaboration). The potential for publication bias was
examined using the funnel plot method.
3. Results
We identified 66 citations in MEDLINE, PubMed, CINAHL,
and CENTRAL databases, and by manual searches of rele-
vant journals. Of these, 15 were review articles, case se-
ries, or basic science papers. In total, 39 dealt with non-
relevant outcomes. One trial was excluded for including
preschool children with or without a previous wheezing
history.9 Eleven RCTs, with a total of 1070 patients meeting
the inclusion criteria were included in this analysis.10e20 Of
the 1070 patients, 552 patients who received nebulized HS
(either 3% or 5% saline) were assigned to the treatment
group and 518 patients who received nebulized NS were
assigned to the control group. Details regarding the in-
terventions, the baseline characteristics of the pop-
ulations, age and birth body weight, the HS dosage and
duration, the use of additional medication or not, and the
primary outcome of each RCT are summarized in Table 1.
All 11 studies were double-blind RCTs. Six trials recruited
outpatient or emergency department participants, and five
trials recruited inpatients. Patients with previous wheezing
episodes were excluded in all trials, except one studyreported viral bronchiolitis patients either with or without
wheezing history.17 Patients with severe bronchiolitis, ox-
ygen saturation < 85% on room air, or respiratory failure
requiring mechanical ventilation were also excluded from
all trials. The concentration of HS was 3% in all trials except
for one trial that used both nebulized 5% HS and 3% NS as
the treatment group in comparison with NS as the control
group.15 Bronchodilators (terbutaline, salbutamol, or al-
buterol) were added to the inhalation solution in six
studies, five used epinephrine, and no additional medica-
tion was used in two studies. The duration of treatment
varied from 30 minutes to 5 days among outpatients and
emergency department participants. For inpatients, the
treatment was delivered until discharge. Virological iden-
tification was reported in nine trials and the positive res-
piratory syncytial virus (RSV) rate varied from 42% to 87%.
The risk of bias assessments is described in Table 2. All
included trials had high methodological quality and a low
risk of bias. Blinding of the intervention was found in all
trials. The methods of randomization were adequate in all
trials except one, in which all patients were randomly
assigned to one of four groups according to the consecutive
order of their admission to the short stay unit of the
emergency department,19 rather than by random number
sequence generation. Blinding of the caregivers and in-
vestigators and allocation concealment might not have
been adequate in this trial.
3.1. Effects on duration of hospitalization
Six RCTs provided data regarding the duration of hospital-
ization in both the treatment and the control
groups.11e13,15,20 The pooling of all data revealed that in-
fants treated with nebulized HS had a statistically signifi-
cantly shorter duration of hospitalization compared with
infants treated with nebulized NS (WMD Z 0.96; 95%
CI Z 1.38 to 0.54; p < 0.001; 6 studies, 565 infants,
heterogeneity c2 Z 16.19; p Z 0.01; I2 Z 63%, Figure 1).
3.2. Effects on rate of hospitalization
Five RCTs assessed the efficacy of nebulized HS in reducing
the risk of hospitalization in a total of 430 pa-
tients.10,14,16,17,19 Overall, nebulized HS treatment
Figure 1 The effects of nebulized hypertonic saline treatment compared with normal saline on the duration of hospitalization
(days).
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hospitalization compared with the control (risk
ratio Z 0.59; 95% CI Z 0.37e0.93; p Z 0.02; 5 studies;
heterogeneity c2 Z 0.46; p Z 0.98; I2 Z 0%, Figure 2).
3.3. Effects on rate of readmission
Three emergency department trials provided data
regarding the rate of readmission as an outcome.14e16 The
pooling of all data did not demonstrate any significant
difference in the rate of readmission among infants treated
with nebulized HS compared to those treated with nebu-
lized NS (risk ratioZ 1.08; 95% CIZ 0.68e1.73; pZ 0.74; 3
studies, 366 infants, heterogeneity p Z 0.88; I2 Z 0%,
Figure 3).
3.4. Effects on CS score
Eight trials used the CS score as an outcome. Six of these
trials compared the post-inhalation CS score between in-
fants treated with nebulized HS and infants treated with
nebulized NS during the first 3 days of
treatment.10e12,15,18,20 The baseline CS scores were com-
parable between the two groups in all six trials. On the 1st
post-treatment day, infants treated with nebulized HS had
a significantly lower CS score compared with infants
treated with nebulized NS in both outpatient and inpatient
trials (pooled WMD Z 0.77; 95% CI Z 1.31 to 0.24;
pZ 0.005; 6 studies, 534 infants, heterogeneity p < 0.001;
I2 Z 83%, Figure 4A). On the 2nd day of treatment, a sig-
nificant difference between the treatment and the control
groups was observed (pooled WMD Z 0.85; 95%
CI Z 1.30 to 0.39; p < 0.001; 6 studies, 531 infants,
heterogeneity p < 0.001; I2 Z 79%, Figure 4B). On the 3rd
day of treatment, the pooled results from five trials still
demonstrated a lower post-inhalation CS score in theFigure 2 The effects of nebulized hypertonic saline treatmenttreatment group compared to the control group, with a
WMD of 1.36 (95% CI Z 1.70 to 1.02; p < 0.001, 333
infants, heterogeneity p Z 0.07; I2 Z 54%, Figure 4C).
3.5. Sensitivity analysis and publication bias
A sensitivity analysis was used to assess whether the
methodological quality of the trials may have affected the
results of the meta-analysis. The substitution of the
random-effects model with the fixed model did not change
our initial qualitative interpretation of the pooled treat-
ment effects on all outcomes. Furthermore, the removal of
studies with small patient numbers or a short intervention
period did not alter the results regarding the effects of HS
compared with NS on the duration of hospitalization and
the rate of readmission. There was no evidence of publi-
cation bias as the funnel plots exhibited symmetric patterns
by visual inspection for all outcome measures.
4. Discussion
Our meta-analysis shows that nebulized HS significantly
decreased the duration of hospital stay by approximately 1
day compared with nebulized NS in infants hospitalized
with acute bronchiolitis. This treatment also significantly
reduced the rate of hospitalization among outpatients and
the CS score among outpatients and inpatients with mild-
to-moderate acute bronchiolitis. The risk of readmission
was not different between infants treated with nebulized
HS and NS.
A previous meta-analysis indicated that nebulized HS
might significantly reduce the length of hospital stay among
infants hospitalized with non-severe acute viral bronchio-
litis and improve the CS score in both outpatient and
inpatient populations.6 However, there was no significant
reduction in the rate of hospitalization in the previouscompared with normal saline on the rate of hospitalization.
Figure 3 The effects of nebulized hypertonic saline treatment compared with normal saline on the rate of readmission.
436 Y.-J. Chen et alstudy. Because there were only three trials included in the
meta-analysis on the rate of hospitalization, low statistical
power due to small sample sizes may have played a role in
this negative result. By adding two more recent trials with aFigure 4 The effects of nebulized hypertonic saline treatment
post-treatment (A) Day 1, (B) Day 2, and (C) Day 3.total of 432 patients, our updated meta-analysis showed a
41% reduction in the rate of hospitalization among patients
treated with HS inhalation compared with patients treated
with NS inhalation, which is consistent with the pooledcompared with normal saline on the clinical severity score on
Nebulized HS treatment for acute bronchiolitis 437result reported by the previous meta-analysis. There was no
significant heterogeneity in results between included
studies (I2 statistic Z 0%). Furthermore, after the removal
of one trial with inadequate randomization and allocation
concealment,19 the pooled results of the remaining four
trials still demonstrated the superiority of nebulized HS in
reducing the rate of hospitalization. We believe that our
updated meta-analysis, with more trials and larger sample
sizes with better statistical power, make the conclusion of
the beneficial effect of nebulized HS treatment more suf-
ficiently persuasive. Given the high prevalence and
morbidity of acute bronchiolitis in infants and the economic
burden on the health care system, the superiority of
nebulized HS in reducing both the rate and the duration of
hospitalization should be considered in the treatment of
this commonly observed disease.
The pathophysiology of acute bronchiolitis is charac-
terized by acute inflammation, submucosal edema and
necrosis of epithelial cells lining small airways, diminished
mucus clearance due to dehydration of the airway surface,
increased mucus production, and bronchospasm.3 Thus,
treatments to maintain hydration of the mucosal surface
and to decrease submucosal edema are crucial in acute
bronchiolitis patients. Theoretically, nebulized HS may
improve not only the hydration of the airway surface, but
also the absorption of water from the mucosa and submu-
cosa through hyperosmolarity,21 which result in hydration
of the mucosal surface, decreased submucosal edema, and
improvement of the rheological properties of the mucus,
thereby improving mucus clearance.22
The participants in the included trials received saline
inhalation in conjunction with variable medication,
including bronchodilators, epinephrine, or no medication.
Inhaled bronchodilators and epinephrine are widely used
and studied in the treatment of acute bronchiolitis. How-
ever, the published results are variable and the efficacy is
uncertain. A Cochrane meta-analysis of RCTs provided little
evidence of benefit from bronchodilator inhalation in in-
fants with acute bronchiolitis.23 Another meta-analysis
compared nebulized epinephrine with placebo and
revealed that epinephrine decreased admissions within 24
hours of administration, but it did not affect admission
within 1 week or the length of hospital stay.24 Moreover, a
recent multi-center, double-blind randomized trial evalu-
ated the efficacy of inhaled racemic adrenaline in
moderate-to-severe acute bronchiolitis.25 The length of
hospital stay and improvement in the CS score were similar
in the infants treated with inhaled racemic adrenaline and
the infants treated with placebo. The authors concluded
that inhaled racemic adrenaline was not more effective
than inhaled NS. Moreover, either bronchodilators or
epinephrine was used at the same dose with the same
schedule in both the treatment and the control groups in
the included studies. The only difference in treatment
modality between each treatment group and each control
group was the concentration of nebulized saline. Given all
of the above reasons, we believe that nebulized HS is
beneficial in decreasing both the rate and the duration of
hospitalization in infants with acute bronchiolitis.
The main limitation of our study is related to the quality
of the available RCTs. As previously mentioned, most of the
included trials are of high methodological quality and havea low risk of bias. However, intention-to-treat analysis was
not used in six trials. This analysis strategy includes every
individual who is randomized according to randomized
treatment assignment and maintains prognostic balance
generated from the original random treatment allocation.
Given the small percentage of participants withdrawn after
randomization in the six trials, ranging from 4.8% to 17.3%
of all participants, we believe that the lack of application
of intention-to-treat analysis was unlikely to have caused
significant bias. Furthermore, the sample size of the
included trials was generally small. As more RCTs have been
published in recent years, this updated meta-analysis
should provide more solid evidence on the relevant
outcome measures of acute bronchiolitis in infants.
In conclusion, our meta-analysis demonstrates that
nebulized HS therapy not only reduces the duration of
hospitalization for acute bronchiolitis in infants, but also is
beneficial in decreasing the rate of admission. Due to the
efficacy and cost-effectiveness of the treatment, nebulized
HS should be considered in clinical practice for the treat-
ment of acute bronchiolitis in infants. Further RCTs are
warranted to address the optimal treatment regimen of
nebulized HS in infants with acute bronchiolitis.
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